- Home
- HOLO vs BDRX Comparison
HOLO vs BDRX Comparison
Compare HOLO & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- BDRX
- Stock Information
- Founded
- HOLO 2018
- BDRX 2000
- Country
- HOLO China
- BDRX United Kingdom
- Employees
- HOLO N/A
- BDRX N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- HOLO Technology
- BDRX Health Care
- Exchange
- HOLO Nasdaq
- BDRX Nasdaq
- Market Cap
- HOLO 24.9M
- BDRX 5.8M
- IPO Year
- HOLO N/A
- BDRX N/A
- Fundamental
- Price
- HOLO $4.97
- BDRX $0.88
- Analyst Decision
- HOLO
- BDRX
- Analyst Count
- HOLO 0
- BDRX 0
- Target Price
- HOLO N/A
- BDRX N/A
- AVG Volume (30 Days)
- HOLO 2.0M
- BDRX 3.1M
- Earning Date
- HOLO 01-01-0001
- BDRX 04-11-2025
- Dividend Yield
- HOLO N/A
- BDRX N/A
- EPS Growth
- HOLO N/A
- BDRX N/A
- EPS
- HOLO N/A
- BDRX N/A
- Revenue
- HOLO $39,771,750.00
- BDRX N/A
- Revenue This Year
- HOLO N/A
- BDRX N/A
- Revenue Next Year
- HOLO N/A
- BDRX N/A
- P/E Ratio
- HOLO N/A
- BDRX N/A
- Revenue Growth
- HOLO 42.62
- BDRX N/A
- 52 Week Low
- HOLO $4.16
- BDRX $0.78
- 52 Week High
- HOLO $848.00
- BDRX $41.50
- Technical
- Relative Strength Index (RSI)
- HOLO 41.61
- BDRX 37.66
- Support Level
- HOLO $4.65
- BDRX $0.83
- Resistance Level
- HOLO $5.17
- BDRX $0.97
- Average True Range (ATR)
- HOLO 0.36
- BDRX 0.11
- MACD
- HOLO 0.35
- BDRX 0.00
- Stochastic Oscillator
- HOLO 76.42
- BDRX 18.81
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.